Affiliation:
1. Chonnam National University Hospital
2. Gyeongsang National University
3. Samsung Changwon Hospital, Sungkyunkwan University School of Medicine
Abstract
Abstract
Background: The risk of bleeding and ischemia in patients with acute myocardial infarction (AMI) who have undergone percutaneous coronary intervention (PCI) is a common concern for physicians, with added conflict over prescribing a potent P2Y12 inhibitor. In particular, elderly East Asian patients with diabetes mellitus (DM) invoke a heightened concern.
Methods: We analyzed 839 patients who were enrolled in the Korea Acute Myocardial Infarction Registry-V, older than 75 years, with DM, had an AMI, and had undergone PCI. Propensity score matching (PSM) and cox regression analyses were performed to compare the bleeding and ischemic risks between the two groups. After PSM, 699 patients (ticagrelor: clopidogrel = 233:466) were analyzed. Patients with Bleeding Academic Research Consortium (BARC) type ≥2 bleed and those at ischemic risk were analyzed based on major adverse cardiac and cerebrovascular events.
Results: Cox regression analyses showed the type of antiplatelet therapy did not affect the incidence of BARC type ≥2 bleeds (HR, 1.67; 95% CI: 0.86–3.22). Use of the transradial approach for PCI, use of statins, and successful PCI lowered the risk of bleeding. In contrast, low body mass index (BMI) increased the risk of bleeds. In the aspect of ischemia, there was no difference based on the antiplatelet agents used (HR, 1.00; 95% CI: 0.68–1.46). Low BMI, hemoglobin <9 g/dL, high Killip class, left ventricular ejection fraction <40%, and multivessel disease increased ischemic risk. Post thrombolysis in myocardial infarction flow grade ≥3, use of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers and statins decreased the risk.
Conclusions: In this Korean prospective cohort study, there was no difference in the risks for bleeding and ischemia, based on the use of ticagrelor or clopidogrel, in elderly Korean patients with DM. To determine the optimal antiplatelet agents for these patients, large scale randomized controlled trials are warranted.
Trial registration: KCT0008355
Publisher
Research Square Platform LLC
Reference39 articles.
1. Heart disease and stroke statistics—2021 update;Virani SS;Circulation,2021
2. Multicenter cohort study of acute myocardial infarction in Korea- interim analysis of the Korea acute myocardial infarction Registry-National Institutes of Health registry;Kim JH;Circ J,2016
3. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC);Collet J-P;Eur Heart J,2020
4. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC);Ibanez B;Eur Heart J,2017
5. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS);Valgimigli M;Eur Heart J,2018